News
As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...
The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...
Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...
6don MSN
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.
6d
Barchart on MSNIs Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his ...
CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...
3don MSN
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...
Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results